Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En 24-ukers prospektiv, åpen etikett, multisenter, enarms rPMS-studie i virkelige omgivelser for Atectura®

21. september 2026 oppdatert av: Novartis Pharmaceuticals

En 24-ukers prospektiv, åpen etikett, multisenter, enarms regulatorisk postmarkedsføringsovervåkingsstudie (rPMS) i virkelige omgivelser (obligatorisk av lokal HA-regulering) for Alectura® (QMF149 150/80 μg o.d., QMF149 150/ 160 μg o.d. og QMF149 150/320 μg o.d. Via Breezhaler)

This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.

Studieoversikt

Detaljert beskrivelse

The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study

Studietype

Observasjonsmessig

Registrering (Faktiske)

670

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Busan, Sør -Korea, 48108
        • Novartis Investigative Site
      • Gyeongsangnam Do, Sør -Korea, 51353
        • Novartis Investigative Site
      • Jeju City, Sør -Korea, 63241
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 05505
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 04763
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 06273
        • Novartis Investigative Site
      • Seoul, Sør -Korea, 137 707
        • Novartis Investigative Site
      • Taegu, Sør -Korea, 41944
        • Novartis Investigative Site
      • Ulsan, Sør -Korea, 44033
        • Novartis Investigative Site
    • Dalseo gu
      • Daegu, Dalseo gu, Sør -Korea, 42602
        • Novartis Investigative Site
    • Gangneung si
      • Kangwon Do, Gangneung si, Sør -Korea, 210 711
        • Novartis Investigative Site
    • Gangwon-do
      • Wŏnju, Gangwon-do, Sør -Korea, 26426
        • Novartis Investigative Site
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Sør -Korea, 10380
        • Novartis Investigative Site
      • Guri-si, Gyeonggi-do, Sør -Korea, 11923
        • Novartis Investigative Site
    • Gyeongsangnam-do
      • Jinju, Gyeongsangnam-do, Sør -Korea, 52727
        • Novartis Investigative Site
    • Jeollabuk-do
      • Jeonju, Jeollabuk-do, Sør -Korea, 54907
        • Novartis Investigative Site
    • Jeonlabuk Do
      • Iksan Si, Jeonlabuk Do, Sør -Korea, 54538
        • Novartis Investigative Site
    • Korea
      • Daejeon, Korea, Sør -Korea, 35015
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 100 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.

Beskrivelse

Inclusion Criteria:

  1. Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
  2. Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)

Exclusion Criteria:

  1. Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
  2. Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
  3. Patients participating in other interventional clinical trials

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Atectura inhalation capsule (150/80ug)

Indacaterol acetate/Mometasone furoate; 150/80ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Atectura inhalation capsule (150/160ug)

Indacaterol acetate/Mometasone furoate; 150/160ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Atectura inhalation capsule (150/320ug)

Indacaterol acetate/Mometasone furoate; 150/320ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events and serious adverse events
Tidsramme: 24 weeks

Incidence of AE and SAE will be collected

24 weeks
Incidence of unexpected adverse events and unexpected serious adverse events
Tidsramme: 24 weeks

Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label

24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
change from baseline in trough FEV1
Tidsramme: Baseline, week 12

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.

Baseline, week 12
change from baseline in ACT score
Tidsramme: Baseline, week 12

The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement.

Baseline, week 12
Effective rate and ineffective rate by investigator assessment
Tidsramme: week 12

Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment

week 12
Baseline characteristics of patients showing adverse events/adverse drug reactions
Tidsramme: 24 weeks

The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations.

24 weeks
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
Tidsramme: 12 weeks

Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations

12 weeks
Baseline characteristics of patients in relation to the investigator assessment
Tidsramme: 12 weeks

Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations.

12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. mai 2022

Primær fullføring (Antatt)

24. desember 2026

Studiet fullført (Antatt)

24. desember 2026

Datoer for studieregistrering

Først innsendt

30. november 2021

Først innsendt som oppfylte QC-kriteriene

19. januar 2022

Først lagt ut (Faktiske)

1. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere